Flag of the European Union EU Clinical Trials Register Help

Clinical trials for movement disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    27 result(s) found for: movement disorders. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-003790-41 Sponsor Protocol Number: JAN12006-01 Start Date*: 2015-05-11
    Sponsor Name:Spherium Biomed
    Full Title: Randomised, double-blinded, placebo and active comparator controlled exploratory clinical trial to assess the efficacy and safety of a triple combination of Ibuprofen, magnesium and ascorbic acid ...
    Medical condition: Temporomandibular joint dysfunction syndrome.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000784-33 Sponsor Protocol Number: TacTremorConversion Start Date*: 2017-07-31
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Effect of Envarsus conversion on tacrolimus-associated tremor in renal transplant patients. An open-label, single centre, prospective pharmacodynamic/pharmacokinetic clinical study
    Medical condition: Tacrolimus-associated tremor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044565 Tremor PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001751-17 Sponsor Protocol Number: IIBSP-DON-2022-43 Start Date*: 2023-07-27
    Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
    Full Title: Multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006319-69 Sponsor Protocol Number: 1.0 Start Date*: 2012-10-25
    Sponsor Name:Pedro Villarejo Campos(Hospital Universitario Ciudad Real)
    Full Title: Closed abdomen hyperthermic intraperitoneal chemotherapy with paclitaxel for advanced epithelial ovarian cancer
    Medical condition: ovarian cancer (II,III,IV FIGO staging and tumoral recurrence)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10028584 Myelosuppression LLT
    14.1 10007541 - Cardiac disorders 10006093 Bradycardia PT
    14.1 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    14.1 10017947 - Gastrointestinal disorders 10012727 Diarrhea LLT
    14.1 10017947 - Gastrointestinal disorders 10047700 Vomiting PT
    14.1 10018065 - General disorders and administration site conditions 10028127 Mucositis LLT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003239 Arthralgia PT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10001760 Alopecia PT
    14.1 10021881 - Infections and infestations 10046544 Urinary infection LLT
    14.1 10047065 - Vascular disorders 10021097 Hypotension PT
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028411 Myalgia PT
    14.1 10021881 - Infections and infestations 10038700 Respiratory infection LLT
    14.1 10029205 - Nervous system disorders 10034610 Peripheral neuropathy NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002234-21 Sponsor Protocol Number: IPX203-B16-03 Start Date*: 2019-09-23
    Sponsor Name:Impax Laboratories, LLC
    Full Title: AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10028035 Movement disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001807-19 Sponsor Protocol Number: TV50717-CNS-30081 Start Date*: 2019-11-12
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)
    Medical condition: Dyskinesia in cerebral palsy (DCP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10068804 Athetoid cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003337-15 Sponsor Protocol Number: CLR_18_06 Start Date*: 2019-06-18
    Sponsor Name:Sun Pharma Advanced Research Company (SPARC) Limited
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease
    Medical condition: Early Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-003453-28 Sponsor Protocol Number: SOMCT03 Start Date*: 2022-03-28
    Sponsor Name:SOM Innovation Biotech SA (SOM Biotech)
    Full Title: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with chore...
    Medical condition: Huntington’s Disease with choreic movements.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000087-15 Sponsor Protocol Number: BP39529 Start Date*: 2017-12-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6...
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2018-003148-21 Sponsor Protocol Number: BASICstudy Start Date*: 2019-01-25
    Sponsor Name:NTNU- Norwegian University of Science and Technology
    Full Title: BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache
    Medical condition: Chronic cluster headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000637-43 Sponsor Protocol Number: CTH-301 Start Date*: 2016-05-12
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF...
    Medical condition: "Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (“OFF” Episodes)"
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002244-70 Sponsor Protocol Number: CLIN-60120-452 Start Date*: Information not available in EudraCT
    Sponsor Name:Ipsen Pharma SAS
    Full Title: Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years with Fibrodysplasia Ossi...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-004849-20 Sponsor Protocol Number: 283PD201 Start Date*: 2023-03-22
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001376-42 Sponsor Protocol Number: IC-01-02-5-009 Start Date*: 2021-10-27
    Sponsor Name:Innovacell AG
    Full Title: Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a phase III, randomized, controlled, double blind, two armed clinical study.
    Medical condition: Fecal incontinence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10016296 Fecal incontinence LLT
    20.0 100000004856 10055507 Fecal incontinence aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) AT (Ongoing) PL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003852-18 Sponsor Protocol Number: PTC518-CNS-002-HD Start Date*: 2022-06-02
    Sponsor Name:PTC Therapeutics, INC
    Full Title: A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006794-37 Sponsor Protocol Number: VRDN-001-101 Start Date*: 2022-05-20
    Sponsor Name:Viridian Therapeutics, Inc.
    Full Title: A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and sub...
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004610-95 Sponsor Protocol Number: 228PD201 Start Date*: 2018-05-01
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 ...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003770-14 Sponsor Protocol Number: 3030-202-002 Start Date*: 2018-10-11
    Sponsor Name:Allergan LTD
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irrit...
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) NL (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003679-31 Sponsor Protocol Number: 2015_22 Start Date*: 2016-04-06
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease
    Medical condition: De Novo Parkinson’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) CZ (Completed) PT (Completed) FR (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002301-24 Sponsor Protocol Number: NMD670-02-0001 Start Date*: Information not available in EudraCT
    Sponsor Name:NMD Pharma A/S
    Full Title: A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy
    Medical condition: Type 3 spinal muscular atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10079415 Spinal muscular atrophy type III LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 10:17:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA